ASCO 2024 | Recruitment criteria of the EVEREST-2 trial assessing A2B694 in solid tumors
Salman Punekar, MD, NYU Langone, New York, NY, comments on the Phase I/II EVEREST-2 trial (NCT06051695), which will assess A2B694 in patients with recurrent unresectable, locally advanced, or metastatic solid tumors. Patients with tumors expressing HLA-A*02 and mesothelin will be recruited to receive A2B694, a logic-gated Tmod CAR CAR-T cell. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding – Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
